Debora Barton
Director/Board Member bei AROVELLA THERAPEUTICS LIMITED
Vermögen: 25 753 $ am 31.03.2024
Profil
Debora Barton is an Independent Non-Executive Director at Arovella Therapeutics Ltd.
since 2021.
She is also a Director at the American Cancer Society, Inc. since 2018.
Previously, she served as the Senior VP, Head-Clinical & Safety at Iovance Biotherapeutics, Inc. from 2018 to 2019.
From 2019 to 2022, she held the position of Chief Medical Officer at both CTx Operations, Inc. and Carisma Therapeutics, Inc. Currently, she is the Chief Medical Officer at TScan Therapeutics, Inc. starting from 2022.
Dr. Barton obtained a doctorate degree from Pontifícia Universidade Católica de São Paulo.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.06.2023 | 263 157 ( 0,03% ) | 25 753 $ | 31.03.2024 | |
TSCAN THERAPEUTICS, INC.
-.--% | 13.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Debora Barton
| Unternehmen | Position | Beginn |
|---|---|---|
| AROVELLA THERAPEUTICS LIMITED | Director/Board Member | 10.08.2021 |
American Cancer Society, Inc.
 American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021. | Director/Board Member | 01.05.2018 |
Ehemalige bekannte Positionen von Debora Barton
| Unternehmen | Position | Ende |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 08.04.2024 |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Chief Tech/Sci/R&D Officer | 01.06.2022 |
| CARISMA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.06.2022 |
| IOVANCE BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.11.2019 |
Ausbildung von Debora Barton
| Pontifícia Universidade Católica de São Paulo | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AROVELLA THERAPEUTICS LIMITED | Health Technology |
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| TSCAN THERAPEUTICS, INC. | Health Technology |
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
American Cancer Society, Inc.
American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021. | Commercial Services |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
